qRT-PCR and Western blot analyses revealed that FMN targeted sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor alpha (PPARα), reducing the levels of inflammatory markers, promoting bile flow from hepatocytes to the bile ducts, improving liver and portal vein bile acid transport, and inhibiting ANIT-induced liver injury and cholestasis. Here, SIRT1 is linked to cholestasis.